What Is Retatrutide?
Retatrutide, also known by its development code LY3437943, is an experimental metabolic peptide developed by Eli Lilly.
It is designed to activate three receptors:
GIP receptor
GLP-1 receptor
Glucagon receptor
That combination makes retatrutide a triple hormone receptor agonist.
This is what separates it from several other well-known metabolic medications.
Semaglutide primarily targets GLP-1.
Tirzepatide targets both GIP and GLP-1.
Retatrutide adds glucagon receptor activity to the GIP/GLP-1 combination.
Researchers hope that this third pathway may increase energy expenditure and fat utilization while GIP and GLP-1 help regulate appetite and glucose metabolism.
Why Are Researchers Interested in It?
Retatrutide has generated enormous interest because clinical trials have produced some of the largest average weight-loss results seen with a nonsurgical obesity medication.
In the published Phase 2 obesity trial, participants receiving the 12 mg dose lost an average of approximately 24.2% of their starting body weight after 48 weeks.
Weight loss had not clearly plateaued by the end of that study.
Then the Phase 3 program produced even larger topline results.
In Lilly’s 2026 TRIUMPH-1 study, people without diabetes receiving 12 mg retatrutide lost an average of 28.3% of their body weight at 80 weeks.
Among a subgroup with a starting BMI of at least 35 who continued into an extension, average weight loss reached approximately 30.3% at 104 weeks.
That level of weight reduction is why retatrutide has become one of the most closely watched medications in obesity research.
How Does Retatrutide Work?
Retatrutide combines three different hormonal signals into one molecule.
Each receptor contributes something different.
GLP-1 signaling primarily influences appetite, satiety, gastric emptying, insulin secretion, and glucose regulation.
GIP signaling contributes to glucose-dependent insulin secretion and may interact with adipose tissue and central appetite pathways.
Glucagon signaling has traditionally been associated with raising blood glucose, but it also increases energy expenditure and promotes mobilization of stored energy.
Retatrutide attempts to balance these systems rather than maximizing only one of them.
The result is a compound designed to influence both sides of the energy equation:
how much energy is consumed and how much energy the body uses.
GLP-1 Activity
GLP-1 stands for glucagon-like peptide-1.
It is released naturally after eating.
GLP-1 signaling can:
increase glucose-dependent insulin secretion, reduce inappropriate glucagon secretion, slow gastric emptying, and increase feelings of fullness.
GLP-1 receptor agonists have transformed diabetes and obesity treatment.
Retatrutide includes GLP-1 activity as one part of its three-receptor design.
GIP Activity
GIP stands for glucose-dependent insulinotropic polypeptide.
Like GLP-1, it is an incretin hormone released in response to food.
GIP influences insulin secretion and appears to interact with fat tissue, appetite regulation, and other metabolic pathways.
Tirzepatide demonstrated that combining GIP and GLP-1 receptor activity can produce powerful metabolic effects.
Retatrutide builds on that concept by adding a third hormone pathway.
Why Add Glucagon?
The glucagon component is arguably the most interesting part of retatrutide.
Glucagon is often known simply as the hormone that increases blood glucose.
But that is only part of its physiology.
Glucagon signaling can also increase:
energy expenditure, lipid mobilization, fatty-acid oxidation, and metabolic activity.
Researchers have long suspected that carefully combining glucagon signaling with GLP-1 activity might produce greater fat loss than GLP-1 signaling alone.
GLP-1 can help control appetite and glucose while glucagon may push the body toward greater energy expenditure.
Retatrutide is one of the most advanced attempts to test that idea in humans.
Weight-Loss Research
Retatrutide’s weight-loss data have been particularly striking.
In the Phase 2 obesity study, average weight loss at 48 weeks was approximately:
8.7% with 1 mg
17.1% with 4 mg
22.8% with 8 mg
24.2% with 12 mg
Placebo participants lost approximately 2.1%.
At the 12 mg dose:
100% of participants lost at least 5% of their body weight.
93% lost at least 10%.
83% lost at least 15%.
These were unusually strong results for a 48-week obesity trial.
Phase 3 Results
By 2026, retatrutide had progressed into a large Phase 3 clinical program called TRIUMPH.
Lilly reported positive results from multiple Phase 3 studies.
In TRIUMPH-1, adults with obesity or overweight and at least one related condition but without diabetes lost an average of 28.3% of body weight at the 12 mg dose over 80 weeks.
Participants taking 4 mg lost an average of 19.0%.
Lilly later reported results from TRIUMPH-2 and TRIUMPH-3.
In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes lost up to an average of 20.8% at 80 weeks.
In TRIUMPH-3, adults with severe obesity and established cardiovascular disease lost up to an average of 22.6%.
These results make retatrutide one of the strongest obesity-drug candidates currently in late-stage clinical development.
Retatrutide vs. Tirzepatide
Tirzepatide activates two receptors:
GIP + GLP-1.
Retatrutide activates three:
GIP + GLP-1 + glucagon.
The addition of glucagon is intended to introduce another metabolic mechanism involving energy expenditure and fat metabolism.
This does not automatically mean retatrutide is “better” than tirzepatide.
Direct head-to-head trials are required to answer that properly.
But the magnitude of weight loss observed in retatrutide trials has understandably generated interest in whether triple agonism can push metabolic therapy beyond the dual-agonist approach.
Retatrutide vs. Semaglutide
Semaglutide primarily targets the GLP-1 receptor.
Retatrutide targets GLP-1 plus GIP and glucagon receptors.
So the difference is not simply potency.
The drugs use different receptor strategies.
Semaglutide has extensive clinical experience and multiple approved indications.
Retatrutide remains investigational.
Retatrutide’s trial results suggest triple agonism may ultimately produce greater average weight loss, but regulatory approval, long-term safety, and real-world evidence still matter enormously.
Appetite & Satiety
GLP-1 and GIP signaling can influence appetite centers in the brain.
People taking incretin-based medications frequently report:
earlier fullness, reduced hunger, less interest in food, and fewer food-related thoughts.
Retatrutide is expected to influence many of these same pathways.
Reduced energy intake is therefore an important component of its weight-loss mechanism.
But retatrutide may differ from pure appetite-suppressing strategies because glucagon receptor activity introduces a potential energy-expenditure component as well.
Energy Expenditure
This is one of retatrutide’s most intriguing research areas.
Traditional obesity treatment focuses heavily on reducing food intake.
Retatrutide may potentially act on both intake and expenditure.
Glucagon receptor activation can increase metabolic activity and energy expenditure.
Researchers are studying whether this contributes meaningfully to retatrutide’s unusually large weight-loss results.
If so, triple agonism may represent a broader metabolic strategy than appetite reduction alone.
Fat Metabolism
Glucagon signaling promotes mobilization of stored energy and can increase fatty-acid oxidation.
Combined with lower caloric intake from GLP-1 and GIP pathways, this creates a biologically interesting environment for reduction of stored body fat.
Retatrutide research therefore involves more than changes on a scale.
Researchers are interested in changes in:
fat mass, visceral adiposity, liver fat, insulin sensitivity, lipid metabolism, and broader cardiometabolic health.
Type 2 Diabetes Research
Retatrutide has also been studied in people with type 2 diabetes.
Its GIP and GLP-1 activity provides a strong mechanistic basis for glucose regulation.
In the 2026 TRIUMPH-2 Phase 3 study, Lilly reported average A1C reductions of up to approximately 1.6 percentage points alongside substantial weight loss.
This is important because obesity and type 2 diabetes frequently share underlying metabolic dysfunction.
A therapy capable of producing major weight reduction while improving glucose control could have broad cardiometabolic implications.
Cardiovascular Research
Obesity is strongly associated with cardiovascular disease.
Researchers are therefore interested not only in whether retatrutide reduces weight, but whether it improves outcomes connected with cardiovascular risk.
TRIUMPH-3 specifically studied adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes.
Lilly reported substantial weight reduction in that population in 2026.
Long-term cardiovascular-outcome data remain especially important because weight loss itself is only one part of the clinical picture.
Obstructive Sleep Apnea
Obstructive sleep apnea, or OSA, is strongly associated with obesity in many patients.
Excess tissue around the upper airway and metabolic factors can worsen airway collapse during sleep.
Because major weight reduction can improve OSA severity, retatrutide has been studied in people with obesity and moderate-to-severe obstructive sleep apnea as part of the TRIUMPH program.
This expands its research beyond simple weight reduction into obesity-related disease.
Knee Osteoarthritis
Knee osteoarthritis is another obesity-associated condition being studied with retatrutide.
Higher body weight increases mechanical stress on the knee joint.
Adipose tissue can also contribute inflammatory signaling.
Substantial weight loss may therefore reduce both mechanical load and some metabolic contributors to symptoms.
Lilly’s Phase 3 program has included people with obesity and knee osteoarthritis pain, making joint-related outcomes another important area of retatrutide research.
Gastrointestinal Effects
Like other medications that activate GLP-1 pathways, gastrointestinal side effects are common.
In the Phase 2 trial, the most common adverse events were gastrointestinal.
They were generally mild to moderate, occurred more frequently at higher doses, and were partly reduced by beginning at a lower dose and gradually increasing treatment.
Potential effects associated with this drug class can include:
nausea, diarrhea, vomiting, constipation, reduced appetite, and abdominal discomfort.
Gradual dose escalation has therefore been an important part of clinical development.
Heart Rate
The Phase 2 trial also observed dose-dependent increases in heart rate.
These increases peaked around 24 weeks and then declined.
The cardiovascular significance of this effect is one reason large and longer-duration Phase 3 studies are important.
When a medication may eventually be used by millions of people, even relatively small physiological changes require careful study.
Is Retatrutide a Peptide?
Yes.
Retatrutide is a peptide-based molecule engineered to activate the GIP, GLP-1, and glucagon receptors.
It is also modified to produce a much longer duration of action than naturally occurring gut hormones.
The published Phase 2 study describes it as a single peptide conjugated to a fatty-acid-derived moiety, giving it an approximately six-day half-life suitable for once-weekly administration.
Evidence Snapshot
Mechanistic foundation: Strong. GIP, GLP-1, and glucagon receptors are well-established metabolic targets.
Human obesity evidence: Very strong and rapidly developing.
Phase 2 weight-loss evidence: Published randomized controlled human trial showing up to approximately 24.2% average weight loss at 48 weeks.
Phase 3 obesity evidence: Positive topline results reported in 2026, including approximately 28.3% average weight loss at 80 weeks with 12 mg in TRIUMPH-1.
Type 2 diabetes research: Positive Phase 3 results including improvements in weight and A1C.
Cardiometabolic and obesity-complication research: Active and expanding.
Regulatory status: Investigational and not currently FDA approved.
What Do We Know?
Retatrutide clearly produces powerful biological effects in humans.
This is no longer a compound supported primarily by animal models or theoretical mechanisms.
Randomized clinical trials have demonstrated substantial reductions in body weight.
Phase 3 trials have now produced positive results across multiple populations.
Its three-receptor strategy also has a strong biological rationale:
GLP-1 and GIP influence appetite and glucose regulation while glucagon may add effects involving energy expenditure and fat metabolism.
That combination makes retatrutide one of the most important emerging metabolic peptides currently in clinical development.
What Are Researchers Still Trying to Determine?
The biggest remaining questions now involve long-term clinical use.
Researchers need to determine:
long-term cardiovascular outcomes, durability of weight loss, effects after treatment discontinuation, long-term safety, preservation of lean mass, optimal maintenance dosing, effects across different populations, and how retatrutide compares directly with established therapies.
Researchers are also studying how much of retatrutide’s unusually strong effect comes specifically from glucagon receptor activation.
That could help guide development of the next generation of metabolic peptides.
Research & Regulatory Status
As of September 2026, retatrutide remains investigational and has not been approved by the FDA or another regulatory agency. Lilly states that it plans to submit a regulatory application to the FDA in 2027.
The FDA has also specifically warned about products being marketed as retatrutide outside legitimate clinical trials.
Retatrutide is not currently a component of an FDA-approved drug, and the FDA states that it cannot legally be used in compounding under federal law.
This is an especially important distinction because the impressive clinical-trial results involve Lilly’s pharmaceutical-grade investigational product—not unverified products sold online under the same name.
Your Pep Resource Takeaway
Retatrutide may represent the next major step in metabolic peptide development.
Semaglutide demonstrated what targeting GLP-1 could do.
Tirzepatide showed that combining GIP and GLP-1 could push weight reduction even further.
Retatrutide asks the next question:
What happens when glucagon signaling is added to the equation?
So far, the answer has been scientifically impressive.
Published Phase 2 research showed average weight loss approaching one-quarter of starting body weight, and 2026 Phase 3 results have reported averages approaching 30% in some populations.
That places retatrutide in territory historically associated more closely with metabolic surgery than conventional weight-loss medications.
It is still investigational, and approval has not happened yet.
But for researchers interested in obesity, metabolic disease, insulin resistance, type 2 diabetes, appetite regulation, energy expenditure, fat metabolism, GLP-1, GIP, glucagon, and next-generation weight-management medicine, retatrutide is one of the most significant compounds currently under development.
Research Areas / Search Keywords
Retatrutide, LY3437943, retatrutide peptide, retatrutide research, triple agonist, triple hormone agonist, triple receptor agonist, GLP-1 GIP glucagon, GLP-1 peptide, GIP peptide, glucagon receptor agonist, obesity research, weight loss research, weight management, metabolic peptide, metabolism research, metabolic health, obesity medication research, next generation GLP-1, GLP-1 research, incretin therapy, incretin peptide, appetite suppression research, appetite regulation, satiety, food noise research, energy expenditure, metabolic rate research, fat metabolism, fatty acid oxidation, body fat research, visceral fat, body composition, insulin sensitivity, insulin resistance, blood sugar research, glucose control, type 2 diabetes research, A1C research, cardiometabolic health, cardiovascular research, severe obesity, obstructive sleep apnea, OSA research, knee osteoarthritis, obesity and joint pain, TRIUMPH trial, TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, retatrutide Phase 3, retatrutide clinical trial, retatrutide vs tirzepatide, retatrutide vs semaglutide, tirzepatide vs retatrutide, semaglutide vs retatrutide, Mounjaro comparison, Zepbound comparison, Wegovy comparison, triple G peptide, experimental weight loss peptide, investigational obesity drug, once weekly peptide, research peptide, peptide science.
Educational Disclaimer
This profile is provided for educational and research-information purposes only. Retatrutide is an investigational drug and is not currently FDA approved for obesity, diabetes, weight loss, or another medical condition. Published clinical-trial findings involve pharmaceutical-grade investigational retatrutide used under controlled research conditions and should not be applied to products marketed online as “retatrutide.” The FDA states that retatrutide cannot currently be used in compounding under federal law.